CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer ...

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...

The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density ...

LLVM powers the core development tools, operating systems, and most applications at Apple Computer, where it long ago ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

St. Louis will host July workshops and a virtual meeting to present draft zoning development standards, share map updates, ...

PARP inhibitors reshaped oncology when they first reached patients some 10 years ago, but they represent just one entry point into a much larger and more intricate biological network.

Alpha Tau Medical (DRTS) pioneers alpha emitter-based targeted radiation therapy, aiming for highly localized tumor ...

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to receive low single-digit capped royalties on th ...

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class ...

After losing civil service protections, some federal employees now in Schedule Policy/Career fear for their job security and retribution for speaking up.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an ...